Fact CheckerSign in

NCT06880991Recruiting

Development of Patient-Reported Outcome Measures Assessing Tumor Visibility and Appearance Concerns in Neurofibromatosis Type 1: A Qualitative Study

Source: ClinicalTrials.gov · Last updated 16 Oct 2026

Brief summary (registry, in English)

Background: Neurofibromatosis 1 (NF1) is a disease that causes tumors to grow along the nerves. These include plexiform neurofibromas (pNF) and cutaneous neurofibromas (cNF). Both pNF and cNF can be visible to other people. These tumors can affect a person s appearance and quality of life. Researchers want to be able to assess changes in appearance before and after treatment for NF1 tumors. Objective: To see if two questionnaires can help assess people's ratings about the appearance of their pNF and cNF tumors. Eligibility: People aged 8 years and older with pNF and people 12 years and older either with cNF or both pNF and cNF. Adult caregivers of children with pNF and cNF are also needed. Design: Participants will complete questionnaires on paper or by phone, computer, or tablet. They will answer questions about how they look, how they feel, and how they feel about the way they look. Participants will meet in at least 1 remote focus group or individual interview. The meeting will last about 1 hour. Each group will include 3 to 5 people, organized by age: 8 to 11 years, 12 to 17 years, 18 to 29 years, and over 30 years. Adult caregivers will meet in a group with other caregivers. They will discuss their NF1 symptoms; how their tumors look; how they feel about the way their tumors look; and their daily activities. They will give their opinions about 2 questionnaires about appearance. The group and individual meetings will be audio-recorded and transcribed. Information that can reveal individual identities will be removed.

Status (registry)
Recruiting
Study type
Observational
Enrollment
110 (estimated)
First submitted
15 Mar 2025
Start date
29 Apr 2025
Primary completion date
31 Mar 2027
Lead sponsor
National Cancer Institute (NCI)
NCT number
NCT06880991

What you commit to

  • Study type: Observational
  • Planned participants: 110
  • From 29 Apr 2025 to the primary completion date, 31 Mar 2027
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Age

  • If saturation has been met within a particular age group, potential participants from that completed age group will no longer be eligible.

Other

  • Physical or cognitive limitations that would prevent them from being able to participate in a focus group or interview, or unwillingness to do so
  • Since we will aim to have no less than 25 percent of participants from underrepresented\* groups, individuals from represented groups may not be able to participate after we have reached the maximum target for represented groups. Consistent with best practices for scale development and validation, this will help ensure that the measures are appropriate for people from a variety of backgrounds.
    • \* Underrepresented groups are defined as people who identify as African American or Black, American Indian, Alaska Native, Hispanic/Latine, Native Hawaiian, and other Pacific Islander.

Criteria the registry did not label

  • INCLUSION CRITERIA:
  • Participants must self-report a diagnosis of NF1 OR be the caregiver of a child with NF1 (5-17 years old with plexiform neurofibroma \[pNF\] or 12-17 years old with cutaneous neurofibroma \[cNF\])
    • The following for the participant or the caregiver of a child, as appropriate:
  • Participants with NF1 must self-report a pNF and/or cNF tumor(s) that is visible to that individual OR others
  • Caregivers of a child with NF1 must report a pNF and/or cNF tumor(s) that the child has that is visible to the child OR others
  • Age requirements:
    • \>= 8 years old (participants with pNF)
    • \>= 12 years old (participants with cNF)
    • \>= 12 years old (participants with pNF and cNF)
    • \>= 18 years (caregivers)
  • Access to a device with internet
  • Ability to understand English and comfort discussing their medical condition in English
  • The ability of adult participant or caregiver of minor participants to understand and the willingness to sign a written informed consent document

Age in the registry: 5 years to 120 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
National Institutes of Health Clinical Center
Coordinator of this site? Confirm its status
BethesdaUnited StatesRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.